UroGen Pharma Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
UroGen Pharma (URGN) signed a deal with IntraGel Therapeutics, investing up to $7M for rights to develop oncology products and potentially acquire TumoCure. URGN's ZUSDURI generated $50.4M in Q2 2026 revenue, up 73% QoQ, with strong prescriber retention and patent protection extended to 2044. UGN-103 is on track for NDA submission in Q3 2026, and UGN-501 will begin Phase 1 trials in Q4 2026.
UroGen Pharma (URGN), a biotech company with a $2B market cap, is highlighted for its FDA-approved products Jelmyto and Zusduri. Jelmyto treats upper tract cancer, while Zusduri shows strong results in bladder cancer. Analysts expect URGN to turn profitable by FY2027, with earnings growing to $7 per share by FY2030. The stock trades around $42.50, with price targets ranging from $58 to $75.
UroGen Pharma (URGN) reports strong commercial performance of Zusduri, a gel-based therapy for urothelial cancer, and highlights its non-surgical advantages. The company's pipeline, including UGN-103, aims to improve operational efficiency and extend intellectual property. URGN also emphasizes strategic partnerships and a solid cash position to fuel future growth, as discussed in a recent conference call.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning URGN (UroGen Pharma Ltd.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent URGN coverage spans earnings, corporate actions and technology.
In the last 30 days, URGN insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($102K). The most active reporter was Schoenberg Mark, Chief Medical Officer, with 1 filing.
The deal expands UroGen's pipeline and could boost future revenue streams, while strong Q2 results signal growing commercial traction.
Near-term trading focus is on execution toward FY2026 narrowing losses and FY2027 profitability, plus overhang from future Jelmyto generic competition.
Limited impact due to lack of concrete details; traders gain no actionable insight.
Positive trial results and strong earnings suggest upside potential for URGN.
Strong earnings and FDA filing boost outlook.
AlphAI scores every news story that mentions URGN with an AI model for sentiment and relevance, and aggregates insider trades from UroGen Pharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
UroGen Pharma (URGN) signed a deal with IntraGel Therapeutics, investing up to $7M for rights to develop oncology products and potentially acquire TumoCure. URGN's ZUSDURI generated $50.4M in Q2 2026 revenue, up 73% QoQ, with strong prescriber retention and patent protection extended to 2044. UGN-103 is on track for NDA submission in Q3 2026, and UGN-501 will begin Phase 1 trials in Q4 2026.
2 min readUroGen Pharma (URGN), a biotech company with a $2B market cap, is highlighted for its FDA-approved products Jelmyto and Zusduri. Jelmyto treats upper tract cancer, while Zusduri shows strong results in bladder cancer. Analysts expect URGN to turn profitable by FY2027, with earnings growing to $7 per share by FY2030. The stock trades around $42.50, with price targets ranging from $58 to $75.
6 min readUroGen Pharma (URGN) reports strong commercial performance of Zusduri, a gel-based therapy for urothelial cancer, and highlights its non-surgical advantages. The company's pipeline, including UGN-103, aims to improve operational efficiency and extend intellectual property. URGN also emphasizes strategic partnerships and a solid cash position to fuel future growth, as discussed in a recent conference call.
1 min readJefferies maintained a Buy rating and $56 price target for UroGen Pharma (URGN) after rival drug data. URGN stock is up 135% in a year, with 91% gross margins. Q2 2026 revenue was $72.5M, beating estimates, driven by Zusduri sales. Guggenheim raised its target to $58, while H.C. Wainwright set a $75 target.
2 min readUroGen Pharma's (URGN) General Counsel, Jason Drew Smith, sold 1,519 shares for $64,618 and acquired 3,334 shares via restricted stock units. URGN reported Q2 2026 revenue of $72.5M, beating estimates, driven by its bladder-cancer drug ZUSDURI. Guggenheim raised its price target to $58, while H.C. Wainwright set a $75 target.
2 min readUroGen Pharma's CMO Mark Schoenberg sold 871 shares for $37,383 and acquired 1,667 shares via RSU settlement. URGN stock is up 112% YoY, trading at $44.78. Q2 2026 revenue was $72.5M, beating estimates. Guggenheim raised its price target to $58, maintaining a Buy rating.
2 min readUroGen Pharma's General Counsel exercised 3,334 RSUs, converting them into ordinary shares, and sold 1,519 shares at $42.54 each to cover tax withholding. The RSUs were part of a 2023 grant of 10,000 shares, vesting in three annual installments. No 10b5-1 trading plan was reported.
1 min readSchoenberg Mark (Chief Medical Officer) sold 60,677 shares of UroGen Pharma Ltd. (URGN) at $47.05 ($2.85M total) on 2026-08-20.
1 min readUroGen Pharma (URGN) submitted a New Drug Application for UGN-103, a treatment for recurrent bladder cancer, backed by Phase 3 data. The filing could expand its RTGel-based bladder cancer franchise. Analysts project varying revenue and earnings estimates for 2029, with risks including ongoing losses and limited cash runway.
2 min readUroGen Pharma (URGN) invested $7M in IntraGel Therapeutics, a developer of injectable, biodegradable gels for cancer treatment. The deal includes $4M upfront and $3M for milestones. If successful, UroGen may continue development and market the treatment, expanding its oncology pipeline. UroGen reported $100M annual revenue from Jelmyto and $50M from Zusduri in the last quarter.
2 min read
